Direct Lobbying Transparency
| Overall Assessment | Comment | Score |
|---|---|---|
| Limited | Telix Pharmaceuticals provides only limited visibility into its climate-related (in this case, broader public-policy) lobbying. It names a single piece of legislation—the U.S. FIND Act—and notes that it is “actively involved in supporting policy and legislative measures that encourage innovation and promote access for patients, such as the FIND Act in the U.S.”, but no other policies are identified and the company does not explain which provisions of the bill it sought to influence. The description of how it lobbies remains high-level: it says it works to “lift the profile of theranostics, and partner with governments” and leads “industry collaboration with policymakers,” yet it does not specify concrete mechanisms (such as letters, formal submissions, or meetings) or identify the individual agencies or lawmakers it approaches. The intended outcomes are expressed only in general terms—ensuring “appropriate Medicare reimbursement and equitable access to innovative radiopharmaceutical imaging drugs”—without detailing the precise changes, targets, or timelines the company is advocating. As a result, while Telix acknowledges some engagement, it leaves most of the substantive information about policies, methods, and desired results undisclosed. | 1 |